Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab plus chemotherapy versus pembrolizumab plus chemotherapy in participants with untreated metastatic non-squamous non-small cell lung cancer. Livmoniplimab is an investigational drug being developed for the treatment of NSCLC. There are 2 stages to this study. In Stage 1, there are 4 treatment arms. Parti

Trial Details

NCT ID
NCT06236438
Phase
PHASE2 / PHASE3
Sponsor
AbbVie
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Livmoniplimab
  • Budigalimab
  • Pembrolizumab
  • Pemetrexed
  • Cisplatin
  • Carboplatin
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742
  • Pembroke Pines, Florida, United States|26.00315,-80.22394
  • Winter Haven, Florida, United States|28.02224,-81.73286
  • Athens, Georgia, United States|33.96095,-83.37794
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Diagnosis of histologically or cytologically confirmed metastatic nonsquamous non-small cell lung cancer (NSCLC) with no known epidermal growth fac…
  • Must have at least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) v1.1 as determined by the local site Investigator/…
  • Life expectancy of at least 3 months and adequate organ function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →